论文部分内容阅读
当前,国内许多中小型制药企业虽然已经获得了 GMP 认证,但其实际经济效益却并不理想,许多产品的销售利润还仅仅只能够维持生产和销售的费用。究其原因,与国内医药行业的供求失衡及过度的盲目竞争是分不开的。同时,我国加入 WTO 后“洋药”的大举入侵以及国内医药制度的深入改革,也对我国的中小型制药企业的发展产生较大的影响。一、国内中小型制药企业的现状及特点纵观中国中小型制药企业的现状,主要有以下几方面的特点:1、随着各项相关政策、法规的制订和完善,医药市场进一步规范。临床销售的医药产品,因为实行集中招标采购制度,使销售的难度大大增加。同时,国家加大了 OTC 市场的广告监管,企业
At present, although many small and medium-sized pharmaceutical companies in China have gained GMP certification, their actual economic benefits are not satisfactory. The sales profits of many products can only maintain the costs of production and sales. The reason is that it is inseparable from the unbalanced supply and demand and excessive blind competition in the domestic pharmaceutical industry. At the same time, the massive invasion of “foreign drugs” and the in-depth reform of the domestic pharmaceutical system after China’s accession to the WTO have also had a great impact on the development of small and medium-sized pharmaceutical enterprises in our country. First, the status quo and characteristics of domestic small and medium-sized pharmaceutical companies Looking at the status quo of China’s small and medium-sized pharmaceutical companies, mainly in the following aspects: 1, with the formulation and improvement of relevant policies and regulations, the pharmaceutical market to further standardize. Clinical sales of pharmaceutical products, because the implementation of centralized bidding and purchasing system, so that the difficulty of sales increased significantly. At the same time, the state has stepped up OTC market advertising regulation, enterprises